Seeking Alpha

Celsion (CLSN) is out with some upbeat ThermoDox commentary, saying the HEAT study's lead...

Celsion (CLSN) is out with some upbeat ThermoDox commentary, saying the HEAT study's lead European principal investigator Riccardo Lencioni has made two presentations discussing what he says are "post-hoc data that indicate ThermoDox may provide potential for clinically relevant improved progression free survival (PFS) and Overall Survival (OS) outcomes." Shares +14.75% premarket. (Previous: SA contributor spars with CLSN over HEAT study)
Comments (2)
  • Brandond
    , contributor
    Comments (381) | Send Message
     
    There is such an enormous opportunity for this type of treatment if it (or some variation of it) works that the price upside from a little speculative money cannot be ignored. Remember this tock was at $8 a few months ago. Very interesting news today and potential for more patentable science.
    20 Jun 2013, 09:12 AM Reply Like
  • CLSN_CEO
    , contributor
    Comments (2) | Send Message
     
    Look at the history folks...this stock slowly made its way to $8 per share, building support the entire way up all because of Phase 3 trials

     

    Personally, I'd rather see it build up slowly, again building support on the run up as compared to just ripping up. This is a $20 stock and will get there slowly but surely. IMHO

     

    $CLSN for the long haul
    20 Jun 2013, 03:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs